以磨玻璃结节为表现的肺腺癌亚肺叶切除研究综述

doi:10.3969/j.issn.1674-8115.2024.07.014

摘要/Abstract

摘要：

手术是肺癌的主要治疗方式。长期以来，肺叶切除术被认为是治疗局部肺癌的标准术式，而亚肺叶切除术，包括肺楔形切除术与肺段切除术，通常只是一种替代术式，应用于无法耐受根治性手术的患者。然而，随着计算机断层扫描在临床中的广泛应用，肺磨玻璃结节的检出频率不断升高，而这一外科标准也逐渐发生了改变。在持续存在的肺结节中，磨玻璃影（ground glass opacity，GGO）通常预示着良好的预后，通常对应着不典型腺瘤样增生、原位腺癌或以附壁生长型模式为主要成分的腺癌等病理改变。大量的回顾性研究表明，对于这类病灶，亚肺叶切除术能够取得令人满意的治疗效果。来自日本的一系列前瞻性研究证实了对于GGO主导的早期肺癌，亚肺叶切除术同样是一种可选择的根治性手术方案。随访数据表明，这部分患者术后的生存状况与肺叶切除术相比无统计学差异。该文综述了影像学上表现为GGO的肺腺癌的亚肺叶切除研究进展。

关键词: 非小细胞肺癌, 肺腺癌, 肺磨玻璃结节, 亚肺叶切除术

Abstract:

Surgery is the mainstay of lung cancer treatment options. Traditionally, lobectomy has held its place as the gold standard for treating localized lung cancer, while sublobar resection, including wedge resection and segmentectomy, was primarily considered as an alternative, often reserved for patient ineligible to sustain a radical intervention. However, with the widespread application of computed tomography (CT) to clinical practice, the increasing detection rate of pulmonary ground glass nodules (GGNs) has reshaped this landscape. Ground glass opacity (GGO) in persistent lung nodules is an indicative factor of a favorable prognosis, typically corresponding to pathological changes such as atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), or adenocarcinomas predominantly featuring a lepidic growth pattern. A large number of retrospective studies have shown that sublobar resection can achieve satisfactory therapeutic outcomes for such lesions. A series of prospective studies from Japan have confirmed that for early-stage lung cancers dominated by GGOs, sublobar resection is also a viable curative surgical option. The follow-up data showed that there was no statistical difference in the survival status of these patients compared with that of pulmonary lobectomy. This article aims to delve into the role of limited lung resection in the context of lung adenocarcinoma presenting with GGO features.

Key words: non-small cell lung cancer, lung adenocarcinoma, pulmonary ground-glass nodule, sublobar resection

中图分类号:

R734.2

朱鸣阳, 许元元, 任江浩, 黄嘉正, 李若楠, 谭强. 以磨玻璃结节为表现的肺腺癌亚肺叶切除研究综述[J]. 上海交通大学学报（医学版）, 2024, 44(7): 922-927.

ZHU Mingyang, XU Yuanyuan, REN Jianghao, HUANG Jiazheng, LI Ruonan, TAN Qiang. Review of sublobar resection for lung adenocarcinoma with ground-glass presence[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 922-927.

参考文献 60

1	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2	THAI A A, SOLOMON B J, SEQUIST L V, et al. Lung cancer[J]. Lancet, 2021, 398(10299): 535-554.
3	HANSELL D M, BANKIER A A, MACMAHON H, et al. Fleischner society: glossary of terms for thoracic imaging[J]. Radiology, 2008, 246(3): 697-722.
4	COLLINS J, STERN E J. Ground-glass opacity at CT: the ABCs[J]. AJR Am J Roentgenol, 1997, 169(2): 355-367.
5	SUZUKI K, ASAMURA H, KUSUMOTO M, et al. “Early” peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan[J]. Ann Thorac Surg, 2002, 74(5): 1635-1639.
6	KIM Y T. Management of ground-glass nodules: when and how to operate?[J]. Cancers, 2022, 14(3): 715.
7	PEDERSEN J H, SAGHIR Z, WILLE M M, et al. Ground-glass opacity lung nodules in the era of lung cancer CT screening: radiology, pathology, and clinical management[J]. Oncology, 2016, 30(3): 266-274.
8	NAKATA M, SAEKI H, TAKATA I, et al. Focal ground-glass opacity detected by low-dose helical CT[J]. Chest, 2002, 121(5): 1464-1467.
9	ENGELER C E, TASHJIAN J H, TRENKNER S W, et al. Ground-glass opacity of the lung parenchyma: a guide to analysis with high-resolution CT[J]. AJR Am J Roentgenol, 1993, 160(2): 249-251.
10	KURIYAMA K, SETO M, KASUGAI T, et al. Ground-glass opacity on thin-section CT: value in differentiating subtypes of adenocarcinoma of the lung[J]. AJR Am J Roentgenol, 1999, 173(2): 465-469.
11	KODAMA K, HIGASHIYAMA M, YOKOUCHI H, et al. Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning[J]. Lung Cancer, 2001, 33(1): 17-25.
12	KIM E A, JOHKOH T, LEE K S, et al. Quantification of ground-glass opacity on high-resolution CT of small peripheral adenocarcinoma of the lung: pathologic and prognostic implications[J]. AJR Am J Roentgenol, 2001, 177(6): 1417-1422.
13	CHO S, YANG H, KIM K, et al. Pathology and prognosis of persistent stable pure ground-glass opacity nodules after surgical resection[J]. Ann Thorac Surg, 2013, 96(4): 1190-1195.
14	WOOD D E, KAZEROONI E A, BAUM S L, et al. Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2018, 16(4): 412-441.
15	HERBST R S, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
16	REA G, RUDRAPPA M. Lobectomy [M]. StatPearls. Treasure Island (FL): StatPearls Publishing: 2022.
17	CAHAN W G. Radical lobectomy[J]. J Thorac Cardiovasc Surg, 1960, 39: 555-572.
18	GINSBERG R J, RUBINSTEIN L V. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group[J]. Ann Thorac Surg, 1995, 60(3): 615-622; discussion 622-623.
19	LANDRENEAU R J, SUGARBAKER D J, MACK M J, et al. Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer[J]. J Thorac Cardiovasc Surg, 1997, 113(4): 691-698; discussion 698-700.
20	STRAND T E, ROSTAD H, MØLLER B, et al. Survival after resection for primary lung cancer: a population based study of 3211 resected patients[J]. Thorax, 2006, 61(8): 710-715.
21	SCOTT W J, HOWINGTON J, FEIGENBERG S, et al. Treatment of non-small cell lung cancer stage I and stage II: accp evidence-based clinical practice guidelines (2nd edition)[J]. Chest, 2007, 132(3 Suppl): 234S-242S.
22	POSTMUS P E, KERR K M, OUDKERK M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): esmo Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4): iv1-iv21.
23	JENSIK R J, FABER L P, MILLOY F J, et al. Segmental resection for lung cancer. a fifteen-year experience[J]. J Thorac Cardiovasc Surg, 1973, 66(4): 563-572.
24	AOKAGE K, YOSHIDA J, HISHIDA T, et al. Limited resection for early-stage non-small cell lung cancer as function-preserving radical surgery: a review[J]. Jpn J Clin Oncol, 2017, 47(1): 7-11.
25	WARREN W H, FABER L P. Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma. five-year survival and patterns of intrathoracic recurrence[J]. J Thorac Cardiovasc Surg, 1994, 107(4): 1087-1093; discussion 1093-1094.
26	SIENEL W, STREMMEL C, KIRSCHBAUM A, et al. Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and width of resection margins: implications for patient selection for segmentectomy[J]. Eur J Cardiothorac Surg, 2007, 31(3): 522-527;discussion 527-528.
27	OU S H, ZELL J A, ZIOGAS A, et al. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19, 702 stage I patients in the California Cancer Registry from 1989 to 2003[J]. Cancer, 2007, 110(7): 1532-1541.
28	BANDO T, YAMAGIHARA K, OHTAKE Y, et al. A new method of segmental resection for primary lung cancer: intermediate results[J]. Eur J Cardiothorac Surg, 2002, 21(5): 894-899; discussion900.
29	BANDO T, MIYAHARA R, SAKAI H, et al. A follow-up report on a new method of segmental resection for small-sized early lung cancer[J]. Lung Cancer, 2009, 63(1): 58-62.
30	WATANABE S, WATANABE T, ARAI K, et al. Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography[J]. Ann Thorac Surg, 2002, 73(4): 1071-1075.
31	EL-SHERIF A, FERNANDO H C, SANTOS R, et al. Margin and local recurrence after sublobar resection of non-small cell lung cancer[J]. Ann Surg Oncol, 2007, 14(8): 2400-2405.
32	OKADA M, NISHIO W, SAKAMOTO T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection[J]. J Thorac Cardiovasc Surg, 2005, 129(1): 87-93.
33	SAKURAI H, DOBASHI Y, MIZUTANI E, et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment[J]. Ann Thorac Surg, 2004, 78(5): 1728-1733.
34	YAMADA S, KOHNO T. Video-assisted thoracic surgery for pure ground-glass opacities 2 cm or less in diameter[J]. Ann Thorac Surg, 2004, 77(6): 1911-1915.
35	SAWABATA N, OHTA M, MATSUMURA A, et al. Optimal distance of malignant negative margin in excision of nonsmall cell lung cancer: a multicenter prospective study[J]. Ann Thorac Surg, 2004, 77(2): 415-420.
36	SCHUCHERT M J, PETTIFORD B L, KEELEY S, et al. Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer[J]. Ann Thorac Surg, 2007, 84(3): 926-933.
37	LI X F, REN F, WANG S H, et al. The epidemiology of ground glass opacity lung adenocarcinoma: a network-based cumulative meta-analysis[J]. Front Oncol, 2020, 10: 1059.
38	NAKAMURA H, SAJI H, OGATA A, et al. Lung cancer patients showing pure ground-glass opacity on computed tomography are good candidates for wedge resection[J]. Lung Cancer, 2004, 44(1): 61-68.
39	TSUTANI Y, MIYATA Y, NAKAYAMA H, et al. Appropriate sublobar resection choice for ground glass opacity-dominant clinical stage IA lung adenocarcinoma: wedge resection or segmentectomy[J]. Chest, 2014, 145(1): 66-71.
40	NAKATA M, SAWADA S, YAMASHITA M, et al. Objective radiologic analysis of ground-glass opacity aimed at curative limited resection for small peripheral non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2005, 129(6): 1226-1231.
41	NAKAYAMA H, YAMADA K, SAITO H, et al. Sublobar resection for patients with peripheral small adenocarcinomas of the lung: surgical outcome is associated with features on computed tomographic imaging[J]. Ann Thorac Surg, 2007, 84(5): 1675-1679.
42	OKADA M, NAKAYAMA H, OKUMURA S, et al. Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma[J]. J Thorac Cardiovasc Surg, 2011, 141(6): 1384-1391.
43	WILSHIRE C L, LOUIE B E, MANNING K A, et al. Radiologic evaluation of small lepidic adenocarcinomas to guide decision making in surgical resection[J]. Ann Thorac Surg, 2015, 100(3): 979-988.
44	ASAMURA H, CHANSKY K, CROWLEY J, et al. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2015, 10(12): 1675-1684.
45	MACCHIARINI P, FONTANINI G, HARDIN M J, et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer[J]. J Thorac Cardiovasc Surg, 1993, 106(1): 80-89.
46	ICHINOSE Y, YANO T, YOKOYAMA H, et al. The correlation between tumor size and lymphatic vessel invasion in resected peripheral stage I non-small-cell lung cancer. A potential risk of limited resection[J]. J Thorac Cardiovasc Surg, 1994, 108(4): 684-686.
47	KOIKE T, TERASHIMA M, TAKIZAWA T, et al. Clinical analysis of small-sized peripheral lung cancer[J]. J Thorac Cardiovasc Surg, 1998, 115(5): 1015-1020.
48	MATSUGUMA H, YOKOI K, ANRAKU M, et al. Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: a predictor of lymph node metastasis[J]. J Thorac Cardiovasc Surg, 2002, 124(2): 278-284.
49	OHDE Y, NAGAI, YOSHIDA J, et al. The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma[J]. Lung Cancer, 2003, 42(3): 303-310.
50	SUZUKI K, KOIKE T, ASAKAWA T, et al. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201)[J]. J Thorac Oncol, 2011, 6(4): 751-756.
51	TRAVIS W D, BRAMBILLA E, NOGUCHI M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary[J]. Proc Am Thorac Soc, 2011, 8(5): 381-385.
52	RUSSELL P A, WAINER Z, WRIGHT G M, et al. Does lung adenocarcinoma subtype predict patient survival? : a clinicopathologic study based on the new international association for the study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification[J]. J Thorac Oncol, 2011, 6(9): 1496-1504.
53	MANDREKAR J N. Simple statistical measures for diagnostic accuracy assessment[J]. J Thorac Oncol, 2010, 5(6): 763-764.
54	SUZUKI K, WATANABE S I, WAKABAYASHI M, et al. A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer[J]. J Thorac Cardiovasc Surg, 2022, 163(1): 289-301.e2.
55	SAJI H, OKADA M, TSUBOI M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial[J]. Lancet, 2022, 399(10335): 1607-1617.
56	MACMAHON H, NAIDICH D P, GOO J M, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the fleischner society 2017[J]. Radiology, 2017, 284(1): 228-243.
57	SUZUKI K, SAJI H, AOKAGE K, et al. Comparison of pulmonary segmentectomy and lobectomy: safety results of a randomized trial[J]. J Thorac Cardiovasc Surg, 2019, 158(3): 895-907.
58	HUANG T W, LIN K H, HUANG H K, et al. The role of the ground-glass opacity ratio in resected lung adenocarcinoma[J]. Eur J Cardiothorac Surg, 2018, 54(2): 229-234.
59	KOIKE W, IWANO S, MATSUO K, et al. Doubling time calculations for lung cancer by three-dimensional computer-aided volumetry: effects of inter-observer differences and nodule characteristics[J]. J Med Imaging Radiat Oncol, 2014, 58(1): 82-88.
60	CHANG B, HWANG J H, CHOI Y H, et al. Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan[J]. Chest, 2013, 143(1): 172-178.

[1]	吴雷, 杜凤麟, 赵明娜, 任逸喆, 张先洲, 娄加陶. N型蛋白酪氨酸磷酸酶受体在肺腺癌中的表达及其促进肿瘤转移的机制[J]. 上海交通大学学报（医学版）, 2025, 45(7): 846-857.
[2]	张先洲, 杜凤麟, 吴雷, 任逸喆, 赵明娜, 娄加陶. OGT通过ERK信号通路促进非小细胞肺癌增殖的机制研究[J]. 上海交通大学学报（医学版）, 2025, 45(10): 1288-1297.
[3]	杜芳, 周凌云, 陈姣, 刘丹波, 向泓先, 陈海飞. 复发难治性多发性骨髓瘤伴多病灶髓外浸润合并肺腺癌1例报道[J]. 上海交通大学学报（医学版）, 2025, 45(1): 122-128.
[4]	许万星, 王琳, 郭巧梅, 王薛庆, 娄加陶. 多模态肺结节诊断模型的临床验证及应用价值探索[J]. 上海交通大学学报（医学版）, 2024, 44(8): 1030-1036.
[5]	刘晨茜, 韩林, 杨轶, 周韩, 刘亚云, 盛德乔. GPR87通过激活RHO/ROCK通路促进非小细胞肺癌的侵袭和迁移[J]. 上海交通大学学报（医学版）, 2024, 44(12): 1514-1525.
[6]	王梦菲, 杨守志, 乔永霞, 黄琳. 基于临床检验指标建立肺腺癌患者浸润程度判别模型[J]. 上海交通大学学报（医学版）, 2024, 44(1): 98-107.
[7]	黄华艳, 徐张闻笛, 夏立亮, 虞永峰, 陆舜. 表皮生长因子受体突变型晚期非小细胞肺癌免疫治疗的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(5): 611-618.
[8]	赵卓明, 刘振浩, 鲁曼曼, 张钰, 许林锋, 谢鹭. 基于TCR组库分析流程的非小细胞肺癌特征分析[J]. 上海交通大学学报（医学版）, 2023, 43(12): 1520-1528.
[9]	廖雅慧, 刘丽云, 朱泓睿, 林厚文, 严继舟, 孙凡. 海绵来源的smenospongine通过抑制非小细胞肺癌细胞中的EGFR-Akt-ABCG2信号通路抑制顺铂耐药[J]. 上海交通大学学报（医学版）, 2022, 42(8): 997-1007.
[10]	刘子杨, 王小文, 陈力. lncRNA GK-IT1通过调控醛缩酶A影响非小细胞肺癌细胞的恶性进展[J]. 上海交通大学学报（医学版）, 2022, 42(5): 591-601.
[11]	陆文清, 孟周文理, 虞永峰, 陆舜. 非小细胞肺癌第三代表皮生长因子受体-酪氨酸激酶抑制剂的耐药机制及治疗策略[J]. 上海交通大学学报（医学版）, 2022, 42(4): 535-544.
[12]	赵雪, 董春燕. WD40重复蛋白43在肺腺癌中的表达及其对细胞紫杉醇耐药的影响[J]. 上海交通大学学报（医学版）, 2022, 42(12): 1656-1665.
[13]	李若楠, 陈小科, 许元元, 谭强. ⅠB~ⅢA期非小细胞肺癌患者术后辅助靶向治疗研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(11): 1612-1619.
[14]	张宇, 吴晓渊, 管丽华, 刘译远, 彭星月, 谢海燕, 胡玮, 郝可可, 夏宁, 陆国军, 侯志波. 高通量药物敏感性筛选系统在非小细胞肺癌伴恶性胸腔积液治疗中的应用[J]. 上海交通大学学报(医学版), 2022, 42(1): 82-89.
[15]	熊雷, 易茜, 许明芳, 陈健. MRPL12在肺腺癌中的表达和预后分析[J]. 上海交通大学学报(医学版), 2021, 41(8): 1033-1040.